Impact of Catheter Ablation of Frequent Premature Ventricular Complexes in Treating Subtle Left Cardiomyopathy

Exclusion Criteria

• •Multiple co-morbidities that may be potential factors affecting functional capacity including anemia, Chronic obstructive pulmonary disease (COPD), interstitial pulmonary fibrosis, bronchial asthma, Cerebrovascular stroke (CVS), skeletomuscular abnormalities or chronic kidney disease (CKD).
• •Symptoms including but not limited to fatigue, palpitations, dyspnea, chest pain, dizziness, syncope, presyncope, or functional limitation that was defined as less than the lower limit of predicted 6-minute walk distance (6 MWD).
• •Any electrolyte abnormalities, abnormal arterial blood gases, and/or abnormal thyroid profile.
• •Ischemic heart disease (ISHD), in our study ISHD was defined as patients with a previous history of Myocardial infarction, acute coronary syndrome, previous revascularization with percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG), or objective evidence of myocardial ischemia including noninvasive functional assessment or coronary angiography showing significant stenosis \> 50%.
• •Symptomatic or asymptomatic structural heart disease including any congenital heart diseases, significant valvular lesion defined as primary or secondary valvular lesion causing abnormal loading condition, or more than grade I diastolic dysfunction.
• •Any symptomatic or asymptomatic phenotype of cardiomyopathies.
• •Polymorphic PVCs.
• •Atrial fibrillation.
• •Positive family history of sudden cardiac death.
• •Heart failure including heart failure with preserved ejection fraction (HFpEF), heart failure with mildly reduced ejection fraction (HFmrEF), and heart failure with reduced ejection fraction (HFrEF).